These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11499735)

  • 1. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.
    Stanek B; Frey B; Hülsmann M; Berger R; Sturm B; Strametz-Juranek J; Bergler-Klein J; Moser P; Bojic A; Hartter E; Pacher R
    J Am Coll Cardiol; 2001 Aug; 38(2):436-42. PubMed ID: 11499735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.
    Berger R; Huelsman M; Strecker K; Bojic A; Moser P; Stanek B; Pacher R
    Circulation; 2002 May; 105(20):2392-7. PubMed ID: 12021226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
    Frantz RP; Lowes BD; Grayburn PA; White M; Krause-Steinrauf H; Krishnan V; Uyeda L; Burnett JC;
    J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
    Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
    Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.
    Isnard R; Pousset F; Chafirovskaïa O; Carayon A; Hulot JS; Thomas D; Komajda M
    Am Heart J; 2003 Oct; 146(4):729-35. PubMed ID: 14564330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.
    Omland T; Aakvaag A; Bonarjee VV; Caidahl K; Lie RT; Nilsen DW; Sundsfjord JA; Dickstein K
    Circulation; 1996 Jun; 93(11):1963-9. PubMed ID: 8640969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
    Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
    J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure.
    Pacher R; Stanek B; Hülsmann M; Koller-Strametz J; Berger R; Schuller M; Hartter E; Ogris E; Frey B; Heinz G; Maurer G
    J Am Coll Cardiol; 1996 Mar; 27(3):633-41. PubMed ID: 8606275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group.
    Richards AM; Nicholls MG; Yandle TG; Ikram H; Espiner EA; Turner JG; Buttimore RC; Lainchbury JG; Elliott JM; Frampton C; Crozier IG; Smyth DW
    Heart; 1999 Feb; 81(2):114-20. PubMed ID: 9922344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
    Richards AM; Doughty R; Nicholls MG; Macmahon S; Ikram H; Sharpe N; Espiner EA; Frampton C; Yandle TG
    Circulation; 1999 Feb; 99(6):786-92. PubMed ID: 9989964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure.
    Selvais PL; Robert A; Ahn S; van Linden F; Ketelslegers JM; Pouleur H; Rousseau MF
    J Card Fail; 2000 Sep; 6(3):201-7. PubMed ID: 10997745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations.
    Groenning BA; Nilsson JC; Sondergaard L; Kjaer A; Larsson HB; Hildebrandt PR
    Eur J Heart Fail; 2001 Dec; 3(6):699-708. PubMed ID: 11738222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure.
    Groenning BA; Nilsson JC; Hildebrandt PR; Kjaer A; Fritz-Hansen T; Larsson HB; Sondergaard L
    Eur J Heart Fail; 2002 Oct; 4(5):635-46. PubMed ID: 12413508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure.
    Lee SC; Stevens TL; Sandberg SM; Heublein DM; Nelson SM; Jougasaki M; Redfield MM; Burnett JC
    J Card Fail; 2002 Jun; 8(3):149-54. PubMed ID: 12140807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
    Frantz RP; Olson LJ; Grill D; Moualla SK; Nelson SM; Nobrega TP; Hanna RD; Backes RJ; Mookadam F; Heublein D; Bailey KR; Burnett JC
    Am Heart J; 2005 Mar; 149(3):541-7. PubMed ID: 15864245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Olivier A; Girerd N; Michel JB; Ketelslegers JM; Fay R; Vincent J; Bramlage P; Pitt B; Zannad F; Rossignol P;
    Int J Cardiol; 2017 Aug; 241():344-350. PubMed ID: 28284500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure.
    Gabrielli O; Puyó AM; De Rosa A; Armando I; Barontini M; Levin G
    Auton Autacoid Pharmacol; 2002; 22(5-6):261-8. PubMed ID: 12866806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
    Vantrimpont P; Rouleau JL; Ciampi A; Harel F; de Champlain J; Bichet D; Moyé LA; Pfeffer M
    Eur Heart J; 1998 Oct; 19(10):1552-63. PubMed ID: 9820995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population.
    McDonagh TA; Cunningham AD; Morrison CE; McMurray JJ; Ford I; Morton JJ; Dargie HJ
    Heart; 2001 Jul; 86(1):21-6. PubMed ID: 11410555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction.
    Richards AM; Nicholls MG; Yandle TG; Frampton C; Espiner EA; Turner JG; Buttimore RC; Lainchbury JG; Elliott JM; Ikram H; Crozier IG; Smyth DW
    Circulation; 1998 May; 97(19):1921-9. PubMed ID: 9609085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.